1. Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004;39:115-128.PMID:
15269615.
2. Alaish SM, Smith AD, Timmons J, et al. Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host. Gut Microbes 2013;4:292-305.PMID:
23652772.
3. Assimakopoulos SF, Vagianos CE, Nikolopoulou VN. Intestinal barrier dysfunction in obstructive jaundice: current concepts in pathophysiology and potential therapies. Ann Gastroenterol 2007;20:116-123.
4. Assimakopoulos SF, Vagianos CE, Patsoukis N, Georgiou C, Nikolopoulou V, Scopa CD. Evidence for intestinal oxidative stress in obstructive jaundice-induced gut barrier dysfunction in rats. Acta Physiol Scand 2004;180:177-185.PMID:
14738476.
5. Brown WR, Kloppel TM. The liver and IgA: immunological, cell biological and clinical implications. Hepatology 1989;9:763-784.PMID:
2651270.
6. Wells CL, Jechorek RP, Erlandsen SL. Inhibitory effect of bile on bacterial invasion of enterocytes: possible mechanism for increased translocation associated with obstructive jaundice. Crit Care Med 1995;23:301-307.PMID:
7867356.
7. Parks RW, Stuart Cameron CH, Gannon CD, Pope C, Diamond T, Rowlands BJ. Changes in gastrointestinal morphology associated with obstructive jaundice. J Pathol 2000;192:526-532.PMID:
11113871.
8. Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg 2010;2:61-69.PMID:
21160852.
9. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269-282.PMID:
19669378.
10. Welsh FK, Ramsden CW, MacLennan K, et al. Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 1998;227:205-212.PMID:
9488518.
11. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005;2:416-422.PMID:
16265432.
12. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3-20.PMID:
19560575.
13. Thuijls G, Derikx JP, Grootjans J, Buurman WA, van Waardenburg DA. Intestinal barrier loss in sepsis. Neth J Crit Care 2011;15:199-203.
14. Holmes JH 4th, Lieberman JM, Probert CB, et al. Elevated intestinal fatty acid binding protein and gastrointestinal complications following cardiopulmonary bypass: a preliminary analysis. J Surg Res 2001;100:192-196.PMID:
11592792.
15. Derikx JP, Evennett NJ, Degraeuwe PL, et al. Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. Gut 2007;56:1473-1475.PMID:
17872576.
16. Hanssen SJ, Derikx JP, Vermeulen Windsant IC, et al. Visceral injury and systemic inflammation in patients undergoing extracorporeal circulation during aortic surgery. Ann Surg 2008;248:117-125.PMID:
18580215.
17. de Haan JJ, Lubbers T, Derikx JP, et al. Rapid development of intestinal cell damage following severe trauma: a prospective observational cohort study. Crit Care 2009;13:R86PMID:
19505335.
18. Derikx JP, Bijker EM, Vos GD, et al. Gut mucosal cell damage in meningococcal sepsis in children: relation with clinical outcome. Crit Care Med 2010;38:133-137.PMID:
19730255.
19. Pelsers MM, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine: tissue distribution and clinical utility. Clin Biochem 2003;36:529-535.PMID:
14563446.
20. Derikx JP, Vreugdenhil AC, Van den Neucker AM, et al. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 2009;43:727-733.PMID:
19359998.
21. Toledo A, Yamaguchi J, Wang JY, Bass BL, Turner DJ, Strauch ED. Taurodeoxycholate stimulates intestinal cell proliferation and protects against apoptotic cell death through activation of NF-kappaB. Dig Dis Sci 2004;49:1664-1671.PMID:
15573924.
22. Yamaguchi J, Toledo A, Bass BL, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery 2004;135:215-221.PMID:
14739857.
23. McConnell KW, Coopersmith CM. Epithelial cells. Crit Care Med 2005;33:S520-S522.PMID:
16340439.
24. Parks RW, Halliday MI, McCrory DC, et al. Host immune responses and intestinal permeability in patients with jaundice. Br J Surg 2003;90:239-245.PMID:
12555304.
25. Sun XQ, Fu XB, Zhang R, et al. Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats. World J Gastroenterol 2001;7:555-558.PMID:
11819828.
26. Assadian A, Assadian O, Senekowitsch C, et al. Plasma D-lactate as a potential early marker for colon ischaemia after open aortic reconstruction. Eur J Vasc Endovasc Surg 2006;31:470-474.PMID:
16376117.
27. Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-1713.PMID:
17050894.
28. Soeters PB, Luyer MD, Greve JW, Buurman WA. The significance of bowel permeability. Curr Opin Clin Nutr Metab Care 2007;10:632-638.PMID:
17693749.